Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
2 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Erasca, Inc.’s names, not what it holds today.
Patents granted
2
2 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against 1 in 2024 and 1 in 2023
Applications published
24
5 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Erasca, Inc. its own name
named as the applicant on its applications, in US
24 publishedERASCA, INC. its own name
US, as the owner printed on each patent
0 published
Newest grantseach row opens the USPTO’s own copy
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Oct 9, 2025 | 2025/0313577 | TRICYCLIC PYRIDONES AND PYRIMIDONES | Pharmaceuticals | Erasca, Inc. |
| Jun 19, 2025 | 2025/0195533 | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | Pharmaceuticals | Erasca, Inc. |
| May 8, 2025 | 2025/0144094 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | Organic fine chemistry | Erasca, Inc. |
| Apr 17, 2025 | 2025/0120978 | JAK INHIBITOR WITH ERK1/2 AND/OR SHP2 INHIBITORS COMBINATION THERAPY | Pharmaceuticals | Erasca, Inc. |
| Feb 6, 2025 | 2025/0043012 | ANTIBODIES AGAINST EGFR AND THEIR USES | Biotechnology | Erasca, Inc. |
| Dec 19, 2024 | 2024/0415843 | USES OF TRI-SUBSTITUTED HETEROARYL DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATASE INHIBITORS | Pharmaceuticals | Erasca, Inc. |
| Nov 21, 2024 | 2024/0383988 | ANTIBODIES AGAINST EGFR AND THEIR USES | Biotechnology | Erasca, Inc. |
| Nov 21, 2024 | 2024/0383921 | AMIDE AND UREA-CONTAINING TRICYCLIC KRAS INHIBITORS | Organic fine chemistry | Erasca, Inc. |
| Sep 19, 2024 | 2024/0307392 | ERK1/2 AND EGFR INHIBITORS COMBINATION THERAPY | Pharmaceuticals | Erasca, Inc. |
| Sep 12, 2024 | 2024/0299388 | ERK1/2 AND SHP2 INHIBITORS COMBINATION THERAPY | Pharmaceuticals | Erasca, Inc. |
What it applied for, 2024 to 2025: Pharmaceuticals 14 · Organic fine chemistry 3 · Biotechnology 2.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.